What are the treatment options for locally advanced Ovarian Cancer

Treatment Options for Locally Advanced Ovarian Cancer

I'm glad you're asking about this—understanding your treatment options is an important part of managing your care. Let me walk you through what "locally advanced" means and the main approaches doctors use.

What Does "Locally Advanced" Mean?

Locally advanced ovarian cancer typically refers to Stage III disease, where cancer has spread beyond the ovary to other areas in the pelvis and/or abdomen, but hasn't spread to distant organs like the lungs or liver. This is an important distinction because it affects which treatments are recommended.

---

PRIMARY TREATMENT APPROACHES

According to NCCN Guidelines for Ovarian Cancer, there are two main pathways for treating locally advanced disease:

Option 1: Primary Debulking Surgery (PDS) Followed by Chemotherapy

What it involves:

• A gynecologic oncologist performs surgery to remove as much cancer as possible (called "debulking")
• This includes removing the uterus, ovaries, fallopian tubes, and other affected tissue
• Surgery is followed by platinum-based chemotherapy (usually within 6 weeks)

Why this approach:

• The NCCN Guidelines emphasize that having a gynecologic oncologist perform your surgery improves survival outcomes compared to general surgeons
• The goal is "optimal cytoreduction"—removing all visible disease or leaving only very small amounts

Chemotherapy options after surgery typically include:

• Intravenous (IV) platinum-based chemotherapy (carboplatin + paclitaxel)
• IV/Intraperitoneal (IP) combination chemotherapy (delivering drugs both through the vein and directly into the abdominal cavity)
• IP chemotherapy plus bevacizumab (an anti-angiogenesis drug that cuts off blood supply to tumors)

---

Option 2: Neoadjuvant Chemotherapy (NACT) Followed by Interval Debulking Surgery

What it involves:

• You receive chemotherapy FIRST (typically 3-4 cycles)
• Then surgery is performed to remove remaining disease
• Followed by additional chemotherapy to complete treatment

When this approach is preferred: According to NCCN Guidelines, NACT is considered for patients who:

• Are poor surgical candidates due to advanced age, frailty, or poor performance status
• Have significant medical conditions that make surgery risky
• Have disease that appears unlikely to be completely removed with upfront surgery
• Need medical improvement before surgery

Why this works:

• Chemotherapy can shrink tumors, making surgery safer and more effective
• It allows time to improve your overall health before surgery
• Studies show it can achieve similar survival outcomes to upfront surgery in appropriate patients

---

MAINTENANCE THERAPY (After Initial Treatment)

This is increasingly important. According to NCCN Guidelines, after you complete chemotherapy, your doctor may recommend maintenance therapy to help prevent or delay recurrence:

Options include:

• Bevacizumab continuation (if you received it during chemotherapy)
• PARP inhibitors (if you have a BRCA mutation or HRD-positive status)
• Observation (watching carefully with imaging and tumor markers)

The choice depends on your specific tumor characteristics and how well you responded to initial treatment.

---

IMPORTANT MOLECULAR TESTING

Before treatment decisions are finalized, the NCCN Guidelines recommend comprehensive tumor testing to identify:

• BRCA1/2 mutations (affects maintenance therapy options)
• HRD (Homologous Recombination Deficiency) status (predicts PARP inhibitor benefit)
• Other biomarkers (MSI, MMR, TMB, BRAF, FRα, RET, NTRK)

This testing helps personalize your treatment plan.

---

KEY QUESTIONS TO ASK YOUR ONCOLOGY TEAM

1. Am I a good candidate for upfront surgery, or should I consider neoadjuvant chemotherapy first? (This depends on your overall health, age, and extent of disease)

2. Which chemotherapy regimen do you recommend—IV alone, IV/IP combination, or IP with bevacizumab? (Each has different side effect profiles)

3. What are my tumor's molecular characteristics, and do I have BRCA mutations or HRD status? (This affects maintenance therapy options)

4. What maintenance therapy do you recommend after chemotherapy? (This varies based on your response and tumor characteristics)

5. How will you monitor me during and after treatment? (Imaging, CA-125 tumor markers, physical exams)

6. What are the potential side effects of each option, and how will they be managed?

---

IMPORTANT CONTEXT

The NCCN Guidelines emphasize that treatment decisions should be individualized. Your specific situation—your age, overall health, extent of disease, tumor characteristics, and personal preferences—all matter. There isn't one "right" answer for everyone; rather, your oncology team will recommend the approach most likely to help you while considering your quality of life.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.